FDA advisers wary of expanding quetiapine use: clinicians air concerns about metabolic effects, tardive dyskinesia.
Kate
K
Traynor
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D016757:Death, Sudden, Cardiac / Q000209:etiology*; D003865:Major Depressive Disorder / Q000188:drug therapy; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D006801:Humans; D024821:Metabolic Syndrome / Q000139:chemically induced*; D000069348:Quetiapine Fumarate; D012307:Risk Factors; D014481:United States; D014486:United States Food and Drug Administration; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate